logo
  

Spectrum Pharma Announces Equity Investment By Hanmi Pharma - Quick Facts

Spectrum Pharmaceuticals (SPPI) announced an equity investment by Hanmi Pharmaceutical along with revisions to the licensing agreements for ROLONTIS and poziotinib. Hanmi entered into a $20 million equity purchase agreement that will be priced at $1.60 per share. Amendments to the licensing agreements for both ROLONTIS and poziotinib will
result in the conversion of the upfront milestone payments for both products to
deferred royalties. The parties also entered into an amended supply arrangement
that is expected to result in a lower cost of goods sold for Spectrum.

Tom Riga, CEO of Spectrum Pharma, said: "We look forward to our continued partnership with Hanmi and to achieving the shared goal of gaining FDA approval for ROLONTIS and poziotinib."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ryanair Holdings Plc reported Monday a loss in its fiscal year 2022, narrower than last year, with strong growth in traffic and load factor. Looking ahead, the company said it expects to return to reasonable profitability in fiscal 2023. Shares of the low fares airline were losing around 4 percent in the morning trading in Germany. The U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS has issued a public health alert against Weis Markets' ready-to-eat or RTE General Tso Chicken meals due to misbranding and undeclared milk, a known allergen. The RTE General Tso Chicken meals were prepared, labeled and sold in the Deli area at Weis Markets stores between April 13 and May 11, 2022. Deutsche Telekom AG on Friday raised its fiscal 2022 adjusted earnings forecast after reporting significantly higher net profit in its first quarter. Shares of the German telecom major were gaining around 1 percent in the morning trading in Germany. For fiscal 2022, the company now expects to post adjusted EBITDA AL of more than 36.6 billion euros.
RELATED NEWS
Follow RTT